In response to these challenges, innovative therapies are emerging. One promising group of medications is GLP-1 receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy) and tirzepatide (Mounjaro). Originally developed for diabetes, these drugs help by improving insulin sensitivity, slowing gastric emptying to promote satiety, and potentially interacting with estrogen receptors, which may be crucial during menopause. These interactions can help regulate appetite and address imbalances in hunger-related hormones like ghrelin and leptin.
